Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
2024 full-year revenue guidance raised by US$ 2 billion
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
In clinical trials, treatment proved more effective than other therapies evaluated
Subscribe To Our Newsletter & Stay Updated
